ClinicalTrials.gg
CompletedNCT05415722Updated Mar 12, 2025Results posted

DUET Study: A Clinical Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of Orally Administered TERN-501 as Monotherapy and in Combination With TERN-101 in Noncirrhotic Adults With Presumed Non-Alcoholic Steatohepatitis

A Phase 2 interventional study of TERN-501 and TERN-101 in NASH - Nonalcoholic Steatohepatitis, sponsored by Terns, Inc.. Completed at 35 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-03-12.

Sponsored by Terns, Inc. (part of Merck & Co., Inc) · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
162
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 11 studies in Non-alcoholic Fatty Liver Disease by Merck & Co., Inc — none open to participants now, none under way, none of them phase 3. Non-alcoholic Fatty Liver Disease · Merck & Co., Inc.

Enrollment
3rd of 10
162 · median 113
Started
2022
the only one that year
Phase 2
7 of 11
none open now
Registered
7th of 11
by date

Among the 11 studies in Non-alcoholic Fatty Liver Disease by Merck & Co., Inc, this one is the 3rd largest by enrollment of the 10 interventional ones that give a count, is the only one that started in 2022, is one of 7 in phase 2, and was the 7th registered.

Non-alcoholic Fatty Liver Disease

1,618 studies on the registry are indexed under Non-alcoholic Fatty Liver Disease; 322 are open to participants now.

Browse Non-alcoholic Fatty Liver Disease studies →

Open to participants now

None of the 11 studies in Non-alcoholic Fatty Liver Disease by Merck & Co., Inc is open now. The open studies under Non-alcoholic Fatty Liver Disease, anywhere →

Who these studies take

Of the 219 Non-alcoholic Fatty Liver Disease studies recruiting now, 66 (30%) set no upper age limit and 124 (57%) stop at 75 or younger; 27 take children under 18; 55 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 11 studies in Non-alcoholic Fatty Liver Disease by Merck & Co., Inc as a file.
02

Study summary

This is a Phase 2a Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Study to Evaluate the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Orally Administered TERN-501 as Monotherapy as well as in Combination with TERN-101 in Noncirrhotic Adults with Presumed Non-Alcoholic Steatohepatitis (NASH)

03

Conditions studied

  • NASH - Nonalcoholic Steatohepatitis

Keywords

  • Nonalcoholic steatohepatitis (NASH)
  • FXR agonist
  • Nonalcoholic Fatty Liver Disease (NAFLD)
  • THR-β agonist
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Male or female, 18 to 75 years of age
  • Overweight or obese with a (BMI) ≥ 25 kg/m2
  • Presumed NASH diagnosed by prior and/or imaging criteria
  • Written

Key Exclusion Criteria:

  • History or clinical evidence of chronic liver diseases other than NAFLD
  • History or known clinical evidence of cirrhosis, esophageal varices, hepatic decompensation or other severe liver impairment,
  • History of liver transplant, or current placement on a liver transplant list
  • Current diagnosis or history of pituitary or thyroid disorders - except for patients with primary hypothyroidism on a stable dose of thyroid hormone replacement therapy.
  • Abnormal TSH or free T4 levels
  • Weight loss of > 5% total body weight within 3 months prior to Screening
  • Uncontrolled diabetes
  • Uncontrolled hyperlipidemia
  • Unstable cardiovascular disease
  • Excessive alcohol consumption

Other protocol-defined I/E criteria that apply.

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
162 participants (actual)

Study arms

  • Experimental
    Arm 1: TERN-501 1 mg

    Orally administered.

    Drug: TERN-501

  • Experimental
    Arm 2: TERN-501 3 mg

    Orally administered.

    Drug: TERN-501

  • Experimental
    Arm 3: TERN-501 6 mg

    Orally administered.

    Drug: TERN-501

  • Experimental
    Arm 4: TERN-501 3 mg + TERN-101 10 mg

    Orally administered.

    Drug: TERN-501 · Drug: TERN-101

  • Experimental
    Arm 5: TERN-501 6 mg + TERN-101 10 mg

    Orally administered.

    Drug: TERN-501 · Drug: TERN-101

  • Experimental
    Arm 6:TERN-101 10 mg

    Orally administered.

    Drug: TERN-101

  • Placebo comparator
    Arm 7: Matching placebo

    Orally administered.

    Other: Placebo

Interventions

  • DrugTERN-501

    Investigational drug

  • DrugTERN-101

    Investigational drug

  • OtherPlacebo

    Matching placebo

06

What researchers measure

Primary outcomes

  1. Relative Change From Baseline in MRI-PDFF at Week 12 for TERN-501 Monotherapy (Arms 1, 2 and 3) Compared to Placebo.

    Magnetic Resonance Imaging Proton Density Fat Fraction (MRI-PDFF) is a non-invasive imaging technique that measures fat content in tissue, particularly in the liver. Relative change from baseline is calculated for each subject as 100 x \[(Week 12 Value - Baseline Value)/Baseline Value\].

    Time frame: 12 weeks

Secondary outcomes

  1. Change From Baseline in cT1 Relaxation Time at Week 12 for TERN-501 Monotherapy (Arms 1, 2 and 3) Compared to Placebo

    Corrected T1 (cT1) is a quantitative MRI relaxation parameter that measures liver inflammation and fibrosis. Change from baseline is calculated for each subject as (Week 12 Value - Baseline Value).

    Time frame: 12 weeks

  2. Relative Change From Baseline in MRI-PDFF at Week 12 for TERN-501+TERN-101 Combination (Arms 4 and 5) Compared to Placebo

    Magnetic Resonance Imaging Proton Density Fat Fraction (MRI-PDFF) is a non-invasive imaging technique that measures fat content in tissue, particularly in the liver. Relative change from baseline is calculated for each subject as 100 x \[(Week 12 Value - Baseline Value)/Baseline Value\].

    Time frame: 12 weeks

  3. Change From Baseline in cT1 Relaxation Time at Week 12 for TERN-501+TERN-101 Combination (Arms 4 and 5) Compared to Placebo

    Corrected T1 (cT1) is a quantitative MRI relaxation parameter that measures liver inflammation and fibrosis. Change from baseline is calculated for each subject as (Week 12 Value - Baseline Value).

    Time frame: 12 weeks

  4. Number and Percentage of Participants With Any Treatment Emergent Adverse Event for All Treatment Groups (Threshold of 0%)

    This outcome measures the number and percentage of participants with any Treatment Emergent Adverse Event (TEAE) for All Treatment Groups (0% Threshold). TEAEs by System Organ Class and Preferred Term meeting the 5% Threshold are reported in the Other Adverse Events section.

    Time frame: 16 weeks

07

Results

Posted Mar 12, 2025

Participant flow

Participant flow — Overall Study
MilestoneArm 1: TERN-501 1 mgArm 2: TERN-501 3 mgArm 3: TERN-501 6 mgArm 4: TERN-501 3 mg + TERN-101 10 mgArm 5: TERN-501 6 mg + TERN-101 10 mgArm 6:TERN-101 10 mgArm 7: Matching Placebo
Started23232223232424
Treated23232223232424
Discontinued treatment0010000
Completed23202219212321
Not completed0304213
Withdrew: Lost to follow-up0201001
Withdrew: Physician decision0001001
Withdrew: Protocol violation0001000
Withdrew: Sponsor discretion0000110
Withdrew: Withdrawal by subject0101101

Outcome measures

PrimaryRelative Change From Baseline in MRI-PDFF at Week 12 for TERN-501 Monotherapy (Arms 1, 2 and 3) Compared to Placebo.

Magnetic Resonance Imaging Proton Density Fat Fraction (MRI-PDFF) is a non-invasive imaging technique that measures fat content in tissue, particularly in the liver. Relative change from baseline is calculated for each subject as 100 x \[(Week 12 Value - Baseline Value)/Baseline Value\].

Time frame:
12 weeks
Reported as:
Least squares mean · Percent change from baseline
Relative Change From Baseline in MRI-PDFF at Week 12 for TERN-501 Monotherapy (Arms 1, 2 and 3) Compared to Placebo.
Percent change from baselineArm 1: TERN-501 1 mgArm 2: TERN-501 3 mgArm 3: TERN-501 6 mgArm 7: Matching Placebo
Relative Change From Baseline in MRI-PDFF at Week 12 for TERN-501 Monotherapy (Arms 1, 2 and 3) Compared to Placebo.-15.39 ± 5.186-27.48 ± 5.740-44.81 ± 5.856-4.01 ± 5.416
Statistical analysis
  • Arm 1: TERN-501 1 mg vs Arm 7: Matching Placebo · ANCOVA · p = 0.1303 · Mean difference (final values): -11.39 · 95% CI -26.178 to 3.406
  • Arm 2: TERN-501 3 mg vs Arm 7: Matching Placebo · ANCOVA · p = 0.0036 · Mean difference (final values): -23.47 · 95% CI -39.140 to -7.799
  • Arm 3: TERN-501 6 mg vs Arm 7: Matching Placebo · ANCOVA · p = <0.0001 · Mean difference (final values): -40.80 · 95% CI -56.545 to -25.064
SecondaryChange From Baseline in cT1 Relaxation Time at Week 12 for TERN-501 Monotherapy (Arms 1, 2 and 3) Compared to Placebo

Corrected T1 (cT1) is a quantitative MRI relaxation parameter that measures liver inflammation and fibrosis. Change from baseline is calculated for each subject as (Week 12 Value - Baseline Value).

Time frame:
12 weeks
Reported as:
Least squares mean · msec
Change From Baseline in cT1 Relaxation Time at Week 12 for TERN-501 Monotherapy (Arms 1, 2 and 3) Compared to Placebo
msecArm 1: TERN-501 1 mgArm 2: TERN-501 3 mgArm 3: TERN-501 6 mgArm 7: Matching Placebo
Change From Baseline in cT1 Relaxation Time at Week 12 for TERN-501 Monotherapy (Arms 1, 2 and 3) Compared to Placebo-28.2 ± 14.62-25.6 ± 15.71-72.0 ± 16.123.6 ± 14.92
Statistical analysis
  • Arm 1: TERN-501 1 mg vs Arm 7: Matching Placebo · ANCOVA · p = 0.1289 · Mean difference (final values): -31.9 · 95% CI -73.17 to 9.39
  • Arm 2: TERN-501 3 mg vs Arm 7: Matching Placebo · ANCOVA · p = 0.1790 · Mean difference (final values): -29.3 · 95% CI -72.08 to 13.58
  • Arm 3: TERN-501 6 mg vs Arm 7: Matching Placebo · ANCOVA · p = 0.0008 · Mean difference (final values): -75.7 · 95% CI -119.08 to -32.23
SecondaryRelative Change From Baseline in MRI-PDFF at Week 12 for TERN-501+TERN-101 Combination (Arms 4 and 5) Compared to Placebo

Magnetic Resonance Imaging Proton Density Fat Fraction (MRI-PDFF) is a non-invasive imaging technique that measures fat content in tissue, particularly in the liver. Relative change from baseline is calculated for each subject as 100 x \[(Week 12 Value - Baseline Value)/Baseline Value\].

Time frame:
12 weeks
Reported as:
Least squares mean · Percent change from baseline
Relative Change From Baseline in MRI-PDFF at Week 12 for TERN-501+TERN-101 Combination (Arms 4 and 5) Compared to Placebo
Percent change from baselineArm 4: TERN-501 3 mg + TERN-101 10 mgArm 5: TERN-501 6 mg + TERN-101 10 mgArm 7: Matching Placebo
Relative Change From Baseline in MRI-PDFF at Week 12 for TERN-501+TERN-101 Combination (Arms 4 and 5) Compared to Placebo-20.75 ± 5.713-47.74 ± 5.412-4.01 ± 5.416
Statistical analysis
  • Arm 4: TERN-501 3 mg + TERN-101 10 mg vs Arm 7: Matching Placebo · ANCOVA · p = 0.0358 · Mean difference (final values): -16.74 · 95% CI -32.352 to -1.128
  • Arm 5: TERN-501 6 mg + TERN-101 10 mg vs Arm 7: Matching Placebo · ANCOVA · p = <0.0001 · Mean difference (final values): -43.73 · 95% CI -58.858 to -28.612
SecondaryChange From Baseline in cT1 Relaxation Time at Week 12 for TERN-501+TERN-101 Combination (Arms 4 and 5) Compared to Placebo

Corrected T1 (cT1) is a quantitative MRI relaxation parameter that measures liver inflammation and fibrosis. Change from baseline is calculated for each subject as (Week 12 Value - Baseline Value).

Time frame:
12 weeks
Reported as:
Least squares mean · msec
Change From Baseline in cT1 Relaxation Time at Week 12 for TERN-501+TERN-101 Combination (Arms 4 and 5) Compared to Placebo
msecArm 4: TERN-501 3 mg + TERN-101 10 mgArm 5: TERN-501 6 mg + TERN-101 10 mgArm 7: Matching Placebo
Change From Baseline in cT1 Relaxation Time at Week 12 for TERN-501+TERN-101 Combination (Arms 4 and 5) Compared to Placebo-59.0 ± 16.25-65.5 ± 14.993.6 ± 14.92
Statistical analysis
  • Arm 4: TERN-501 3 mg + TERN-101 10 mg vs Arm 7: Matching Placebo · ANCOVA · p = 0.0053 · Mean difference (final values): -62.6 · 95% CI -106.33 to -18.96
  • Arm 5: TERN-501 6 mg + TERN-101 10 mg vs Arm 7: Matching Placebo · ANCOVA · p = 0.0014 · Mean difference (final values): -69.2 · 95% CI -110.97 to -27.39
SecondaryNumber and Percentage of Participants With Any Treatment Emergent Adverse Event for All Treatment Groups (Threshold of 0%)

This outcome measures the number and percentage of participants with any Treatment Emergent Adverse Event (TEAE) for All Treatment Groups (0% Threshold). TEAEs by System Organ Class and Preferred Term meeting the 5% Threshold are reported in the Other Adverse Events section.

Time frame:
16 weeks
Reported as:
Count of participants · Participants
Number and Percentage of Participants With Any Treatment Emergent Adverse Event for All Treatment Groups (Threshold of 0%)
ParticipantsArm 1: TERN-501 1 mgArm 2: TERN-501 3 mgArm 3: TERN-501 6 mgArm 4: TERN-501 3 mg + TERN-101 10 mgArm 5: TERN-501 6 mg + TERN-101 10 mgArm 6:TERN-101 10 mgArm 7: Matching Placebo
Number and Percentage of Participants With Any Treatment Emergent Adverse Event for All Treatment Groups (Threshold of 0%)11131114121011

Adverse events

Collected over 16 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Arm 1: TERN-501 1 mg0/23 (0%)1/23 (4.3%)2/23 (8.7%)
Arm 2: TERN-501 3 mg0/23 (0%)0/23 (0%)8/23 (34.8%)
Arm 3: TERN-501 6 mg0/22 (0%)0/22 (0%)5/22 (22.7%)
Arm 4: TERN-501 3 mg + TERN-101 10 mg0/23 (0%)0/23 (0%)10/23 (43.5%)
Arm 5: TERN-501 6 mg + TERN-101 10 mg0/23 (0%)0/23 (0%)6/23 (26.1%)
Arm 6:TERN-101 10 mg0/24 (0%)2/24 (8.3%)5/24 (20.8%)
Arm 7: Matching Placebo0/24 (0%)0/24 (0%)5/24 (20.8%)
Most frequent serious events
Most frequent serious events
EventArm 1: TERN-501 1 mgArm 2: TERN-501 3 mgArm 3: TERN-501 6 mgArm 4: TERN-501 3 mg + TERN-101 10 mgArm 5: TERN-501 6 mg + TERN-101 10 mgArm 6:TERN-101 10 mgArm 7: Matching Placebo
PneumoniaInfections and infestations1/230/230/220/230/230/240/24
CellulitisInfections and infestations0/230/230/220/230/231/240/24
AnxietyPsychiatric disorders0/230/230/220/230/231/240/24
Most frequent other events
Most frequent other events
EventArm 1: TERN-501 1 mgArm 2: TERN-501 3 mgArm 3: TERN-501 6 mgArm 4: TERN-501 3 mg + TERN-101 10 mgArm 5: TERN-501 6 mg + TERN-101 10 mgArm 6:TERN-101 10 mgArm 7: Matching Placebo
PruritusSkin and subcutaneous tissue disorders0/232/233/227/234/231/243/24
DiarrhoeaGastrointestinal disorders1/235/232/222/230/231/241/24
Upper respiratory tract infectionInfections and infestations1/230/231/223/230/232/240/24
NasopharyngitisRespiratory, thoracic and mediastinal disorders0/231/232/220/230/231/240/24
HeadacheGeneral disorders1/231/231/222/230/231/242/24
NauseaGastrointestinal disorders0/232/231/221/232/230/240/24

Baseline characteristics

Patients who were randomized and received at least 1 dose of study drug were included in the Efficacy Analysis Set

Age, Categorical
Age, Categorical(Participants)Arm 1: TERN-501 1 mgArm 2: TERN-501 3 mgArm 3: TERN-501 6 mgArm 4: TERN-501 3 mg + TERN-101 10 mgArm 5: TERN-501 6 mg + TERN-101 10 mgArm 6:TERN-101 10 mgArm 7: Matching PlaceboTotal
<=18 years00000000
Between 18 and 65 years18181916202021132
>=65 years553734330
Age, Continuous
Age, Continuous(years)Arm 1: TERN-501 1 mgArm 2: TERN-501 3 mgArm 3: TERN-501 6 mgArm 4: TERN-501 3 mg + TERN-101 10 mgArm 5: TERN-501 6 mg + TERN-101 10 mgArm 6:TERN-101 10 mgArm 7: Matching PlaceboTotal
Median56.0 (27 to 71)55.0 (25 to 73)53.0 (25 to 70)59.0 (32 to 73)56.0 (34 to 71)56.5 (21 to 72)53.5 (32 to 71)55.5 (21 to 73)
Sex: Female, Male
Sex: Female, Male(Participants)Arm 1: TERN-501 1 mgArm 2: TERN-501 3 mgArm 3: TERN-501 6 mgArm 4: TERN-501 3 mg + TERN-101 10 mgArm 5: TERN-501 6 mg + TERN-101 10 mgArm 6:TERN-101 10 mgArm 7: Matching PlaceboTotal
Female1113161111121589
Male12106121212973
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Arm 1: TERN-501 1 mgArm 2: TERN-501 3 mgArm 3: TERN-501 6 mgArm 4: TERN-501 3 mg + TERN-101 10 mgArm 5: TERN-501 6 mg + TERN-101 10 mgArm 6:TERN-101 10 mgArm 7: Matching PlaceboTotal
Hispanic or Latino1713151114101999
Not Hispanic or Latino610712914563
Unknown or Not Reported00000000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Arm 1: TERN-501 1 mgArm 2: TERN-501 3 mgArm 3: TERN-501 6 mgArm 4: TERN-501 3 mg + TERN-101 10 mgArm 5: TERN-501 6 mg + TERN-101 10 mgArm 6:TERN-101 10 mgArm 7: Matching PlaceboTotal
White20221820181922139
Black or African American103332012
American Indian or Alaska Native21001105
Native Hawaiian or Other Pacific Islander00100102
Asian00001001
Not reported00000011
Other (Puerto Rican)00000101
Unknown00000011
08

Study locations

35 sites
  • Site 1017: The Institute for Liver Health dba Arizona Liver Health
    Chandler, Arizona 85224, United States
  • Site 1018: Arizona Liver Health
    Tucson, Arizona 85712, United States
  • Site 1004 Southern California Research Center
    Coronado, California 92118, United States
  • Site 1061 Velocity Clinical Research, Gardena
    Gardena, California 90247, United States
  • Site 1013 University of California, San Diego - Altman Clinical and Translational Research Institute
    La Jolla, California 92037, United States
  • Site 1016 Ruane Clinical Research Group Inc.
    Los Angeles, California 90036, United States
  • Site 1060 Catalina Research Institute, LLC
    Montclair, California 91763, United States
  • Site 1001 National Research Institute
    Panorama City, California 91402, United States
  • Site 1040 Inland Empire Clinical Trials, LLC
    Rialto, California 92377, United States
  • Site 1062 Excel Medical Clinical Trials, LLC
    Boca Raton, Florida 33434, United States
  • Site 1057:Integrity Clinical Research, LLC
    Doral, Florida 33122, United States
  • Site 1041: Florida Research Institute
    Lakewood Ranch, Florida 34211, United States
  • Site 1007: Floridian Clinical Research, LLC
    Miami Lakes, Florida 33016, United States
  • Site 1058 Optimus U Corporation
    Miami, Florida 33125, United States
  • Site 1036 Schiff Center for Liver Diseases / University of Miami
    Miami, Florida 33136, United States
  • Site 1045 University of Miami Hospital & Clinics, Sylvester Comp. Cancer Center
    Miami, Florida 33136, United States
  • Site 1055: Progressive Medical Research
    Port Orange, Florida 32127, United States
  • Site 1032 IU Health University Hospital
    Indianapolis, Indiana 46202, United States
  • Site 1052: Iowa Diabetes and Endocrinology Research Center
    West Des Moines, Iowa 50265, United States
  • Site 1054 Louisiana Research Center
    Shreveport, Louisiana 71105, United States
  • Site 1063 GI Alliance - Flowood
    Flowood, Mississippi 39232, United States
  • Site 1042: Lucas Research, Inc
    Morehead City, North Carolina 28557, United States
  • Site 1059: Premier Medical Group
    Clarksville, Tennessee 37040, United States
  • Site 1044: Quality Medical Research
    Nashville, Tennessee 37211, United States
  • Site 1005:Texas Clinical Research Institute, LLC
    Arlington, Texas 76012, United States
  • Site 1050: Pinnacle Clinical Research
    Austin, Texas 78757, United States
  • Site 1051: South Texas Research Institute
    Edinburg, Texas 78539, United States
  • Site 1043 Liver Specialists of Texas
    Houston, Texas 77030, United States
  • Site 1046 Houston Methodist Hospital
    Houston, Texas 77030, United States
  • Site 1039: Houston Research Institute
    Houston, Texas 77079, United States
  • Site 1003: Clinical Trials of Texas, LLC
    San Antonio, Texas 78215, United States
  • Site 1006: American Research Corporation
    San Antonio, Texas 78215, United States
  • Site 1056: Pinnacle Clinical Research
    San Antonio, Texas 78229, United States
  • Site 1053 Bon Secours Richmond Community Hospital LLC d/b/a Bon Secours Liver Institute of Richmond
    Richmond, Virginia 23236, United States
  • Site 1022 Liver Institute Northwest
    Seattle, Washington 98105, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2022 to primary completion in Jul 2023, 12 months.

Results were first posted in Mar 2025, 1 year 8 months after primary completion.

Of 132 industry-sponsored phase 2 interventional studies under Non-alcoholic Fatty Liver Disease, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 30. This study's 12 months is below that.

Counting every sponsor, half of 185 studies reached it within 26 months; a quarter within 16 and three quarters within 36.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 8, 2022
First posted
Jun 13, 2022
StartActual
Jun 28, 2022
Primary completionActual
Jul 10, 2023
CompletionActual
Jul 10, 2023
Results first posted
Mar 12, 2025
Last update
Mar 12, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 12, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05415722
Lead sponsor
Terns, Inc.
Responsible party
Sponsor
First posted
Jun 13, 2022
Start date
Jun 28, 2022
Primary completion
Jul 10, 2023
Completion
Jul 10, 2023
Results posted
Mar 12, 2025
Last update
Mar 12, 2025

Study contacts

Study Director
study director · Terns, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion